Ashley Brant is a seasoned leader in the bioanalytical industry with over 25 years of experience in driving process improvements that enhance productivity and ensure regulatory compliance across both large and small molecule bioanalytical streams.
Ashley’s career began after earning her biochemistry degree from Eastern Michigan University, performing EGFR receptor research with Elizabeth Butch. She then joined Parke-Davis/Warner Lambert. There, she assessed molecular biological interactions to evaluate the mechanisms of action and safety risks for early drug candidates. This role led her into the biomarker quantitation field and to mastering LC-MS/MS, integrating it with traditional ligand-binding assay methods.
At Pfizer, Ashley expanded her expertise in regulated bioanalysis, developing methods specializing in ligand binding, antibody capture, endogenous molecules, and hybrid platforms, all while adapting to the evolving fast throughput demands of drug development.
She later pursued graduate education at the University of Michigan in the Hakansson lab and transitioned to consulting, honing her skills further in bioanalysis. Over the past 15 years, Ashley has led bioanalytical teams within contract research organizations, overseeing diverse areas such as mass spectrometry, ligand-binding assays, cell-based assays, flow cytometry, immunogenicity, and more.
Currently, Ashley serves as Vice President and leads the global bioanalysis organization at ICON, a global clinical contract research organization (CRO).
Outside of work, Ashley values time with her family, cooking new dishes for them to enjoy and being outdoors. Passionate about community engagement, Ashley has also volunteered on numerous boards supporting educational and athletic opportunities for her community in Michigan.
